Canada · Delayed Price · Currency is CAD New Relic Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of CAD 217.05 million. The enterprise value is 202.66 million.
| Market Cap | 217.05M |
| Enterprise Value | 202.66M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NervGen Pharma has 73.08 million shares outstanding. The number of shares has increased by 17.34% in one year.
| Current Share Class | 73.08M |
| Shares Outstanding | 73.08M |
| Shares Change (YoY) | +17.34% |
| Shares Change (QoQ) | +0.97% |
| Owned by Insiders (%) | 2.40% |
| Owned by Institutions (%) | 3.94% |
| Float | 61.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 156.21 |
| P/TBV Ratio | 231.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.91 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.06 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -253.35% and return on invested capital (ROIC) is -158.74%.
| Return on Equity (ROE) | -253.35% |
| Return on Assets (ROA) | -68.24% |
| Return on Invested Capital (ROIC) | -158.74% |
| Return on Capital Employed (ROCE) | -1,871.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.91% in the last 52 weeks. The beta is 0.64, so NervGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +4.91% |
| 50-Day Moving Average | 3.54 |
| 200-Day Moving Average | 3.17 |
| Relative Strength Index (RSI) | 32.95 |
| Average Volume (20 Days) | 71,178 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.00M |
| Pretax Income | -25.61M |
| Net Income | -25.61M |
| EBITDA | -25.96M |
| EBIT | -26.00M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 14.47 million in cash and 81,838 in debt, giving a net cash position of 14.39 million or 0.20 per share.
| Cash & Cash Equivalents | 14.47M |
| Total Debt | 81,838 |
| Net Cash | 14.39M |
| Net Cash Per Share | 0.20 |
| Equity (Book Value) | 1.39M |
| Book Value Per Share | 0.02 |
| Working Capital | 938,468 |
Cash Flow
| Operating Cash Flow | -17.71M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NervGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.34% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.80% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |